The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Is The Market Size Of The Respiratory Disease Vaccine Market In 2026 And What Value Is Projected For 2030?
The market size for respiratory disease vaccines has experienced a marginal increase in recent years. This market is expected to grow from $70.03 billion in 2025 to $71.36 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 1.9%. The growth witnessed in the past can be ascribed to a high prevalence of respiratory infections, the limited availability of effective vaccines, various government immunization initiatives, advancements in monoclonal antibody research, and an increasing awareness concerning respiratory health.
The respiratory disease vaccine market size is anticipated to experience consistent growth over the coming years. It is projected to expand to $81 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 3.2%. This growth during the forecast period is attributable to the increasing need for universal vaccines, advancements in mRNA and viral vector vaccine technologies, the expansion of cold-chain infrastructure, a rise in public-private partnerships for vaccine distribution, and a concentrated effort on pandemic preparedness and swift responses. Prominent trends for the forecast period involve the creation of next-generation respiratory vaccines, an amplified focus on pediatric and geriatric immunization, the broadening of immunization initiatives in emerging markets, the development of combination vaccines for comprehensive multi-pathogen protection, and the adoption of accelerated vaccine development and distribution frameworks.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12924&type=smp
Which Growth Drivers Are Contributing To The Progress Of The Respiratory Disease Vaccine Market?
The increasing occurrence of tuberculosis (TB) is anticipated to fuel the expansion of the respiratory disease vaccine market. Tuberculosis, an infectious respiratory condition caused by Mycobacterium tuberculosis, primarily impacts the lungs and poses a significant global health threat. The uptick in TB cases stems from factors such as compromised healthcare systems, delays in diagnosis, and broader transmission patterns, all contributing to a greater disease burden. Respiratory disease vaccines are crucial for mitigating TB-associated risks by reducing infection rates, curbing transmission, and bolstering international prevention strategies. For example, in March 2024, the Centers for Disease Control and Prevention, a US-based government agency, reported that tuberculosis cases escalated from 8,320 in 2022 to 9,615 in 2023, marking a rise of 1,295 cases. Consequently, the escalating incidence of tuberculosis is stimulating the growth of the respiratory disease vaccine market.
What Are The Key Segments Of The Respiratory Disease Vaccine Market?
The respiratory disease vaccine market covered in this report is segmented –
1) By Type: Viral Vaccine, Bacterial Vaccine, Combination Vaccine
2) By Infection: COVID-19, Influenza, Respiratory Syncytial Virus (RSV), Pneumonia, Other Infections
3) By Age: Infant, Adolescent, Adult
4) By End-User: Clinic, Hospital, Other End-Users
Subsegments:
1) By Viral Vaccine: Influenza Vaccine, Respiratory Syncytial Virus (RSV) Vaccine, Coronavirus Vaccine
2) By Bacterial Vaccine: Pneumococcal Vaccine, Haemophilus Influenzae Type B (Hib) Vaccine, Pertussis Vaccine
3) By Combination Vaccine: DTaP With Hib And IPV, Pneumococcal Conjugate Vaccine With Influenza Vaccine
What Key Trends Are Influencing The Development Of The Respiratory Disease Vaccine Market?
Key companies active in the respiratory disease vaccine market are focusing on developing innovative products to improve their effectiveness and offer better solutions for preventing and treating respiratory disease infections. For example, in May 2023, Pfizer Inc., a pharmaceutical firm based in the US, obtained Food and Drug Administration (FDA) approval for ABRYSVO (Respiratory Syncytial Virus Vaccine), a bivalent respiratory syncytial virus prefusion F (RSVpreF) vaccine, aimed at preventing lower respiratory tract disease caused by respiratory syncytial virus in individuals aged 60 and above. ABRYSVO is an unadjuvanted vaccine composed of two preF proteins designed to maximize immunity against RSV A and B varieties, and its safety and efficacy have been clinically verified.
Who Are The Leading Companies Operating In The Respiratory Disease Vaccine Market?
Major companies operating in the respiratory disease vaccine market are Pfizer Inc., Johnson & Johnson Ltd., Merck & Co. Inc., Sanofi SA, AstraZeneca PLC, GlaxoSmithKline PLC, Sinovac Biotech Co. Ltd., Moderna Inc., BioNTech SE, CSL Limited, Daiichi Sankyo Company Limited, Mitsubishi Tanabe Pharma Corporation, Novavax Inc., Emergent BioSolutions Inc., Seqirus, Bio Farma, Dynavax Technologies Corporation, Hualan Biological Bacterin Co. Ltd., Serum Institute of India Pvt. Ltd., Bavarian Nordic A/S, Valneva SE, Biological E. Limited, CanSino Biologics Inc., Bharat Biotech International Limited, Medicago Inc, CureVac N.V., Incepta Vaccine Ltd, Inovio Pharmaceuticals Inc., Ology Bioservices, VBI Vaccines Inc.
Read the full respiratory disease vaccine market report here:
https://www.thebusinessresearchcompany.com/report/respiratory-disease-vaccine-global-market-report
What Are The Leading Geographic Regions In The Respiratory Disease Vaccine Market?
Asia-Pacific was the largest region in the respiratory disease vaccine market in 2025. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the respiratory disease vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Respiratory Disease Vaccine Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=12924&type=smp
Browse Through More Reports Similar to the Global Respiratory Disease Vaccine Market 2026, By The Business Research Company
Respiratory Disease Vaccine Market Report 2026
https://www.thebusinessresearchcompany.com/report/respiratory-disease-vaccine-global-market-report
Vaccines Market Report 2026
https://www.thebusinessresearchcompany.com/report/vaccines-global-market-report
Influenza Vaccines Market Report 2026
https://www.thebusinessresearchcompany.com/report/influenza-vaccines-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model